|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-9-19
|
|
pubmed:abstractText |
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1105-8
|
|
pubmed:dateRevised |
2010-4-29
|
|
pubmed:meshHeading |
pubmed-meshheading:18781882-Adult,
pubmed-meshheading:18781882-Anti-HIV Agents,
pubmed-meshheading:18781882-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:18781882-Azetidines,
pubmed-meshheading:18781882-Cholesterol, LDL,
pubmed-meshheading:18781882-Female,
pubmed-meshheading:18781882-HIV Infections,
pubmed-meshheading:18781882-Humans,
pubmed-meshheading:18781882-Hypercholesterolemia,
pubmed-meshheading:18781882-Male,
pubmed-meshheading:18781882-Middle Aged,
pubmed-meshheading:18781882-Placebos
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
|
|
pubmed:affiliation |
University of North Carolina, Chapel Hill, NC 27599, USA. wohl@med.unc.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
